Brandywine Global Investment Management’s Royalty Pharma RPRX Stock Holding History

Brandywine Global Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$61M	Buy	1,579,252 +62,931	+4%	+$2.4M	0.41%	65
2025 Q3	$53.5M	Buy	1,516,321 +256,116	+20%	+$9.27M	0.37%	80
2025 Q2	$45.4M	Sell	1,260,205 -460,171	-27%	-$15.2M	0.32%	84
2025 Q1	$53.6M	Sell	1,720,376 -237,926	-12%	-$7.54M	0.39%	64
2024 Q4	$50M	Buy	1,958,302 +142,176	+8%	+$3.77M	0.36%	78
2024 Q3	$50.6M	Buy	1,816,126 +178,931	+11%	+$4.96M	0.34%	84
2024 Q2	$43.2M	Buy	+1,637,195	New	+$45.4M	0.32%	83

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brandywine Global Investment Management's RPRX Position: Q4 2025 in Review

Brandywine Global Investment Management increased its Royalty Pharma (RPRX) stake by 4.2% in Q4 2025, buying an estimated $2.4M and bringing the position to 1,579,252 shares worth $61M. The position accounts for 0.41% of the portfolio, ranked #65.

Brandywine Global Investment Management first reported a position in RPRX in Q2 2024 and has held it in 7 quarters since. 538 funds tracked by Wall St. Rank hold RPRX as of Q4 2025.

Brandywine Global Investment Management held 1,579,252 shares of Royalty Pharma worth $61M as of Q4 2025.
Brandywine Global Investment Management bought 62,931 Royalty Pharma shares in Q4 2025, an estimated $2.4M.
Royalty Pharma made up 0.41% of Brandywine Global Investment Management's portfolio in Q4 2025, its #65 holding.
Brandywine Global Investment Management first reported a position in Royalty Pharma in Q2 2024 and has held it in 7 quarters since.
538 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2025.

Based on Brandywine Global Investment Management's 13F filing for Q4 2025, filed 11 Feb 2026.